Day Elizabeth, Upadhyay Pratham, Padhiyar Raashi, Tzelves Lazaros, Szabados Bernadett, Ta Anthony, Sridhar Ashwin, Kelly John
Department of Urology University College London Hospital London UK.
Medical School University College London London UK.
BJUI Compass. 2025 Aug 11;6(8):e70062. doi: 10.1002/bco2.70062. eCollection 2025 Aug.
A range of techniques have been described for robotic-assisted intracorporeal neobladder construction. The pyramid neobladder has now been performed for over 10 years. We now describe the long-term outcomes, including the impact of function preservation through nerve and prostate capsule sparing in the male population.
SUBJECTS/PATIENTS AND METHODS: All patients who underwent pyramid neobladder construction between January 2015 and December 2023 at the University College London Hospital (UK) were reviewed. Patients were selected for function preservation based on baseline sexual function/wishes, PSA ± multiparametric prostate MRI. Selected oncological, functional and patient reported outcomes were assessed.
A total of 71 patients were included; 87% (61/71) were men. About 65% (40/61) underwent either nerve- or prostate capsule-sparing surgery. Median follow-up was 57.8 months (IQR 48.3). In male patients, there was no difference between the 12- and 24-month cancer specific and overall survival rates between the function sparing groups. There were no positive prostate cancer margins. Daytime continence was 75% (39/52) and 67% (6/9), and nighttime was 17% (9/52) and 11% (1/9), in men and women, respectively. There was no significant difference between the male function sparing groups ( < 0.342). About 94% of men (29/31) were sexually active before surgery, falling to 55% (17/31) after, with 76% (13/17) using treatment for erectile dysfunction. The median change in SHIM score was 4.5 (SD 5.3) in prostate capsule-sparing, 6 (SD 7.7) in nerve-sparing and 17 (SD 2.8) in standard groups.About 45% (30/66) of patients had a significant reduction in eGFR (>10 mL/min/1.73m). Uretero-ileal strictures were confirmed in 4.2% (3/71). About 28% (19/67) of patients reported recurrent UTIs and 7% (5/71) reported neobladder rupture.
Sexual function had the largest impact on quality of life and may be improved with function-sparing techniques. The burden of additional complications including neobladder rupture and urinary tract infections was also highlighted.
已经描述了一系列用于机器人辅助体内新膀胱构建的技术。棱锥形新膀胱现已实施超过10年。我们现在描述其长期结果,包括在男性人群中通过保留神经和前列腺包膜对功能保留的影响。
受试者/患者与方法:对2015年1月至2023年12月在英国伦敦大学学院医院接受棱锥形新膀胱构建的所有患者进行了回顾。根据基线性功能/意愿、前列腺特异性抗原(PSA)±多参数前列腺磁共振成像(MRI)选择患者进行功能保留。评估了选定的肿瘤学、功能和患者报告的结果。
共纳入71例患者;87%(61/71)为男性。约65%(40/61)的患者接受了保留神经或前列腺包膜的手术。中位随访时间为57.8个月(四分位间距48.3)。在男性患者中,功能保留组在12个月和24个月时的癌症特异性生存率和总生存率之间没有差异。没有前列腺癌切缘阳性情况。男性和女性的日间控尿率分别为75%(39/52)和67%(6/9),夜间控尿率分别为17%(9/52)和11%(1/9)。男性功能保留组之间没有显著差异(<0.342)。约94%的男性(29/31)术前有性功能,术后降至55%(17/31),其中76%(13/17)使用勃起功能障碍治疗。在保留前列腺包膜组中,性功能指数(SHIM)评分的中位变化为4.5(标准差5.3),保留神经组为6(标准差7.7),标准组为17(标准差2.8)。约45%(30/66)的患者估算肾小球滤过率(eGFR)显著降低(>10 mL/min/1.73m²)。输尿管回肠狭窄在4.2%(3/71)的患者中得到证实。约28%(19/67)的患者报告复发性尿路感染,7%(5/71)的患者报告新膀胱破裂。
性功能对生活质量影响最大,保留功能的技术可能会改善性功能。还强调了包括新膀胱破裂和尿路感染在内的额外并发症负担。